NEW ORLEANS, June 20, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to it ...

Summary of the Webinar on Tertiary Lymphoid Structures in Cancer Immunotherapy Company and Industry - **Company**: Sequoia Biosciences - **Industry**: Cancer Immunotherapy and Spatial Biology Core Insights and Arguments 1. **Immunotherapy Efficacy**: Only 30% of cancer patients benefit from immune checkpoint inhibition, indicating a need for better predictive biomarkers to select suitable patients [4][5][6] 2. **Tertiary Lymphoid Structures (TLS)**: The presence of TLS is a major predictor of response to immunotherapy, particularly in sarcoma, renal cancer, and melanoma [5][21] 3. **Sarcoma Treatment Challenges**: Sarcoma, a rare and heterogeneous cancer, has limited treatment options, with standard chemotherapy showing a response rate of less than 10% [7][8] 4. **Clinical Trial Findings**: A clinical trial showed a response rate of only 2% in sarcoma patients without biomarker selection, highlighting the importance of identifying effective biomarkers [10][19] 5. **TLS as a Biomarker**: The presence of TLS in tumors correlates with better outcomes and response rates to immunotherapy, with a significant increase in response rate from 2% to 30% when selecting patients based on TLS status [19][21] 6. **Universal Predictive Value of TLS**: TLS status was found to be a powerful predictor of outcomes across various cancer types, not limited to sarcoma [21][23] 7. **Mechanisms of Resistance**: High levels of T regulatory cells (Tregs) in TLS positive tumors are associated with poor outcomes, while plasma cell infiltration correlates with better outcomes [24][25][26] 8. **Future Directions**: Ongoing research aims to understand the determinants of resistance to immunotherapy in TLS positive tumors and explore new immunotherapy targets [28][29] Other Important Content 1. **Guidelines for TLS Assessment**: Recent guidelines have been published for pathologists to assess TLS status in tumors, emphasizing the importance of standardized approaches [30][39] 2. **Artificial Intelligence in TLS Assessment**: There are emerging technologies using AI and digital pathology to evaluate TLS status, which could streamline the assessment process [39] 3. **Clinical Trials and Research Programs**: The CONDOR program aims to analyze genomic features of sarcomas in relation to TLS status, which may provide further insights into tumor biology and treatment responses [37] 4. **Impact of Tumor Microenvironment**: The tumor microenvironment plays a crucial role in the formation of TLS and the overall immune response, with ongoing studies investigating its components [28][36] This summary encapsulates the key points discussed in the webinar, focusing on the significance of TLS in cancer immunotherapy and the ongoing research efforts to enhance treatment efficacy.

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 100 Campus Drive, 6th Floor Marlborough, Massachusetts 01752 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.34%. A quarter ago, it was expected that this tissue analysis provider would post a loss of $0.15 per share when it actually produced a loss of $0.17, delivering a surprise of -13.33%.Over the last four quarters, the ...

Exhibit 99.1 First Quarter 2025 Business Highlights ● Revenue was $16.6 million in the first quarter of 2025, compared to $18.4 million in the prior year period; a decrease of 9.8%. ● Gross margin was 59.3% in the first quarter of 2025, compared to 45.7% in the prior year period. ● Operating expenses were $23.3 million for the first quarter of 2025, compared to $30.0 million in the prior year period, an improvement of 22.3%. ● Operating loss was $13.4 million for the first quarter of 2025, compared to $21.6 ...

MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. “Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Akoya Biosciences, driven by higher revenues, but actual results compared to estimates will significantly influence stock price movements [1][2]. Financial Expectations - Akoya is expected to report a quarterly loss of $0.29 per share, reflecting a year-over-year change of +17.1% [3]. - Revenues are projected to be $19.88 million, which is an increase of 8.3% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate for Akoya has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate for Akoya is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +20.69%, suggesting a more optimistic outlook from analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. - However, Akoya currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat despite the positive Earnings ESP [11]. Historical Performance - In the last reported quarter, Akoya was expected to post a loss of $0.15 per share but actually reported a loss of $0.17, resulting in a surprise of -13.33% [12]. - Over the past four quarters, Akoya has only beaten consensus EPS estimates once [13]. Industry Comparison - Illumina, another player in the biomedical and genetics industry, is expected to report earnings of $0.96 per share, showing a year-over-year change of +966.7%, with revenues projected at $1.04 billion, down 3.5% from the previous year [17]. - Illumina's consensus EPS estimate has been revised 0.6% lower in the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 0.18%, indicating a likelihood of beating the consensus EPS estimate [18].

Akoya's technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya's PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand ...

Core Viewpoint - Akoya Biosciences reported a quarterly loss of $0.17 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, indicating a surprise of -13.33% [1] - The company has struggled with revenue, posting $21.34 million for the quarter, missing the consensus estimate by 1.05% and down from $26.49 million a year ago [2] Financial Performance - The company has only surpassed consensus EPS estimates once in the last four quarters [2] - Akoya shares have declined approximately 34.5% year-to-date, compared to a 4.1% decline in the S&P 500 [3] Future Outlook - The company's earnings outlook is uncertain, with current consensus EPS estimates of -$0.21 for the next quarter and -$0.64 for the current fiscal year [7] - The estimate revisions trend for Akoya is currently unfavorable, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Akoya belongs, is currently in the top 30% of Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Akoya's stock performance [5]

Financial Performance - Total revenue for the year ended December 31, 2024, was $81.672 million, a decrease of 15.5% compared to $96.633 million in 2023[550] - Product revenue decreased to $53.027 million in 2024 from $67.410 million in 2023, representing a decline of 21.4%[550] - Net loss for 2024 was $55.365 million, compared to a net loss of $63.323 million in 2023, showing an improvement of 12.4%[550] - The company reported a gross profit of $47.878 million for 2024, down from $56.305 million in 2023, reflecting a decrease of 15.0%[550] - For the year ended December 31, 2024, the net loss was $55,365, an improvement from a net loss of $63,323 in 2023, representing a reduction of approximately 11.5%[557] - The company reported a net loss before income taxes of $55,219 for the year ended December 31, 2024, compared to a net loss of $63,283 in 2023, indicating an improvement of approximately 12.5%[691] - Basic and diluted net loss per common share improved to $(1.12) in 2024 from $(1.43) in 2023[706] Cash and Assets - Cash and cash equivalents decreased significantly from $83.125 million in 2023 to $11.779 million in 2024[548] - Total assets decreased from $180.369 million in 2023 to $125.005 million in 2024, a reduction of 30.6%[548] - Total cash equivalents and marketable securities decreased from $76,844 million in 2023 to $31,385 million in 2024[652] - Cash, cash equivalents, and marketable securities totaled $35,040 as of December 31, 2024, with an accumulated deficit of $285,436[561] - The company’s total intangible assets decreased from $17,412 million in 2023 to $14,559 million in 2024[660] - The company had total deferred tax assets of $64,647 as of December 31, 2024, compared to $53,496 in 2023, representing an increase of approximately 20.9%[692] Liabilities and Expenses - Total liabilities decreased from $126.599 million in 2023 to $117.410 million in 2024, a decline of 7.5%[548] - Operating expenses for 2024 were $94.608 million, down from $113.973 million in 2023, a decrease of 16.9%[550] - The company incurred cash paid for interest of $9,178 in 2024, compared to $7,650 in 2023, indicating a 19.9% increase in interest expenses[557] - Total accrued expenses and other current liabilities decreased from $13,433 million in 2023 to $10,848 million in 2024[662] - Operating expenses for compensation and benefits decreased to $46,779,000 in 2024 from $60,895,000 in 2023, a reduction of 23.2%[709] Revenue Breakdown - Revenue from instruments was $23,829 million in 2024, down from $42,095 million in 2023, a decrease of 43.5%[609] - Consumables revenue increased to $28,258 million in 2024, up from $24,134 million in 2023, reflecting a growth of 17.8%[609] - Service and other revenue totaled $28,645 million in 2024, slightly down from $29,223 million in 2023, a decrease of 2.0%[609] - Revenue recognized from contract liabilities was $7,123 million in 2024 and $9,032 million in 2023[616] - Revenue from North America accounted for 62% of total revenue in 2024, slightly up from 60% in 2023, while APAC revenue decreased to 15% from 17%[710] Inventory and Receivables - The company reported a total inventory of $24,321 as of December 31, 2024, up from $17,877 in 2023, reflecting a 36.0% increase[580] - Accounts receivable balance was $13,779 as of December 31, 2024, net of an allowance for credit losses of $960, which increased from $45 in 2022[576] Capital and Financing - The company completed a follow-on public offering in June 2023, raising additional capital to support operations[561] - The Company received approximately $47,817,000 in net proceeds from the Offering of 10,005,000 shares at a public offering price of $5.00 per share[679] - The Company has not sold any shares of common stock under the ATM program as of December 31, 2024, despite having an aggregate offering price of up to $50,000,000[676] Workforce and Operational Changes - In January 2024, the Company initiated a workforce reduction as part of operating expense cost savings initiatives[731] - The workforce reduction was substantially completed by the end of Q1 2024[731] - During the three months ended March 31, 2024, the Company recorded $1,257 million in charges related to the workforce reduction[732] - The Company also incurred $140 million in employee and equipment relocation costs associated with the exit of its Menlo Park facility[732] Impairment and Asset Evaluation - The Company recorded $902 million in impairment related to property and equipment for the three months ended March 31, 2024[656] - The Company evaluates long-lived assets for impairment and concluded that its long-lived assets were not impaired as of December 31, 2024[591] - Goodwill was tested for impairment and determined to be not impaired as of November 1, 2024[592] Stock and Compensation - The Company granted stock options with an aggregate fair value of $3,451,000 in 2024, down from $7,447,000 in 2023, indicating a decrease of 53.6%[683] - The aggregate intrinsic value of options exercised was $571,000 in 2024, compared to $4,330,000 in 2023, representing a decline of 86.8%[685] - The Company granted Restricted Stock Units (RSUs) with an aggregate fair value of $7,915,000 in 2024, down from $13,057,000 in 2023, reflecting a decrease of 39.5%[686] - Total stock-based compensation for the year ended December 31, 2024, was $9,306, a decrease of 10.8% from $10,437 in 2023[688] Accounting Standards and Compliance - The Company follows ASC 606 for revenue recognition, ensuring revenue is recognized when control of goods or services is transferred to customers[595] - The company adopted ASC 2023-07 on December 31, 2024, enhancing segment disclosures in its financial statements[643] - The company is evaluating the impact of ASC Update No. 2023-09 on its consolidated financial statements, effective after December 15, 2024[644]